patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_153939 | REC_0014401 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 4.8 | 72 | female | 1 | 33 | 5.9 | 2 | carboplatin + paclitaxel + pembrolizumab | 21 | true | MSS | 2026-03-15T05:36:00.775100+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_644927 | REC_0014402 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 15 | 16.4 | 52 | male | 0 | 12 | 5.1 | 0 | alectinib 600 mg BID | 55.8 | false | MSS | 2026-03-15T05:36:00.775480+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_918984 | REC_0014403 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 7.2 | 74 | female | 2 | 18 | 5.5 | 5 | carboplatin + paclitaxel + pembrolizumab | 8 | true | MSS | 2026-03-15T05:36:00.775812+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_215344 | REC_0014404 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 19 | 8.5 | 72 | female | 0 | 9 | 4.3 | 4 | pembrolizumab 200 mg q3w | 13.5 | false | MSS | 2026-03-15T05:36:00.777078+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_237918 | REC_0014405 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 34 | 8.2 | 70 | male | 0 | 24 | 4 | 9 | carboplatin + paclitaxel + pembrolizumab | 13.6 | false | MSS | 2026-03-15T05:36:00.777816+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_329023 | REC_0014406 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 21 | 5.5 | 61 | male | 1 | 15 | 5.5 | 1 | pembrolizumab 200 mg q3w | 8.9 | true | MSS | 2026-03-15T05:36:00.778213+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_702487 | REC_0014407 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 31 | 13.7 | 69 | female | 0 | 6 | 7 | 4 | entrectinib 600 mg daily | 10.1 | false | MSI-H | 2026-03-15T05:36:00.778573+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_441324 | REC_0014408 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 7.3 | 67 | male | 1 | 13 | 6.6 | 3 | sotorasib 960 mg daily | 13.3 | false | MSS | 2026-03-15T05:36:00.778901+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_548050 | REC_0014409 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 19 | 10.9 | 63 | male | 1 | 10 | 7 | 2 | sotorasib 960 mg daily | 11.9 | false | MSI-H | 2026-03-15T05:36:00.779238+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_913785 | REC_0014410 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 13.5 | 61 | male | 1 | 17 | 4.5 | 6 | osimertinib 80 mg daily | 9.3 | true | MSI-H | 2026-03-15T05:36:00.779573+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_123172 | REC_0014411 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 21 | 7.7 | 74 | female | 1 | 21 | 5.9 | 0 | alectinib 600 mg BID | 26.9 | true | MSS | 2026-03-15T05:36:00.779902+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_452113 | REC_0014412 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 32 | 10.8 | 54 | male | 0 | 7 | 6.7 | 3 | sotorasib 960 mg daily | 12 | false | MSI-H | 2026-03-15T05:36:00.780336+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_643902 | REC_0014413 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 11.7 | 74 | female | 1 | 20 | 3.7 | 1 | alectinib 600 mg BID | 17.2 | false | MSS | 2026-03-15T05:36:00.780700+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_495653 | REC_0014414 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 12.8 | 62 | male | 1 | 24 | 5.2 | 6 | alectinib 600 mg BID | 4 | false | MSS | 2026-03-15T05:36:00.781014+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_247682 | REC_0014415 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 21 | 9 | 66 | female | 0 | 12 | 5.3 | 1 | entrectinib 600 mg daily | 13.2 | false | MSS | 2026-03-15T05:36:00.781327+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_831467 | REC_0014416 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 28 | 14.8 | 61 | male | 1 | 12 | 6.1 | 2 | pembrolizumab 200 mg q3w | 17.4 | false | MSI-H | 2026-03-15T05:36:00.781647+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_394511 | REC_0014417 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 5.4 | 70 | female | 2 | 16 | 4.5 | 7 | entrectinib 600 mg daily | 11 | false | MSS | 2026-03-15T05:36:00.782001+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_991702 | REC_0014418 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 28 | 8.2 | 78 | female | 2 | 17 | 6.4 | 3 | pembrolizumab 200 mg q3w | 6.2 | false | MSS | 2026-03-15T05:36:00.782506+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_725902 | REC_0014419 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 16 | 15.9 | 77 | female | 2 | 12 | 8.6 | 4 | osimertinib 80 mg daily | 5.5 | true | MSI-H | 2026-03-15T05:36:00.782864+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_486099 | REC_0014420 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 5.5 | 66 | female | 0 | 16 | 4.8 | 6 | osimertinib 80 mg daily | 6.1 | false | MSS | 2026-03-15T05:36:00.783206+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_105384 | REC_0014421 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 32 | 16.8 | 81 | female | 1 | 15 | 3.9 | 4 | sotorasib 960 mg daily | 12.6 | true | MSS | 2026-03-15T05:36:00.783532+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_708349 | REC_0014422 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 32 | 13.8 | 76 | female | 2 | 21 | 3.8 | 2 | osimertinib 80 mg daily | 26.8 | false | MSS | 2026-03-15T05:36:00.783866+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_175544 | REC_0014423 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 27 | 4.3 | 62 | female | 1 | 13 | 2.5 | 4 | pembrolizumab 200 mg q3w | 5.2 | true | MSS | 2026-03-15T05:36:00.784321+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_126682 | REC_0014424 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 8.8 | 59 | male | 1 | 10 | 4.3 | 7 | osimertinib 80 mg daily | 4 | true | MSS | 2026-03-15T05:36:00.784701+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_790734 | REC_0014425 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 28 | 8.8 | 76 | female | 0 | 17 | 6.3 | 1 | osimertinib 80 mg daily | 29.5 | false | MSS | 2026-03-15T05:36:00.785050+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_759250 | REC_0014426 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 31 | 17 | 69 | female | 0 | 11 | 6 | 6 | osimertinib 80 mg daily | 9.2 | true | MSS | 2026-03-15T05:36:00.785400+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_717296 | REC_0014427 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 11.2 | 70 | male | 2 | 21 | 3.8 | 6 | osimertinib 80 mg daily | 19.1 | true | MSI-H | 2026-03-15T05:36:00.785742+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_736332 | REC_0014428 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 11.9 | 53 | male | 0 | 18 | 5.5 | 6 | osimertinib 80 mg daily | 8.2 | true | MSI-H | 2026-03-15T05:36:00.786093+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_114733 | REC_0014429 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 17 | 6.1 | 62 | female | 1 | 14 | 4.6 | 5 | carboplatin + paclitaxel + pembrolizumab | 4 | false | MSS | 2026-03-15T05:36:00.786413+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_529960 | REC_0014430 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 10.7 | 44 | female | 0 | 14 | 5.7 | 4 | osimertinib 80 mg daily | 5.6 | true | MSI-H | 2026-03-15T05:36:00.786786+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_351185 | REC_0014431 | Non-small cell lung cancer | Large cell carcinoma | III | None (PD-L1 high) | 27 | 5.4 | 60 | male | 1 | 8 | 4.7 | 0 | pembrolizumab 200 mg q3w | 47.8 | true | MSS | 2026-03-15T05:36:00.787254+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_146434 | REC_0014432 | Non-small cell lung cancer | Squamous cell carcinoma | III | None (PD-L1 high) | 26 | 3 | 83 | female | 2 | 69 | 5.6 | 0 | pembrolizumab 200 mg q3w | 43 | false | MSS | 2026-03-15T05:36:00.787624+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_738463 | REC_0014433 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 6.9 | 79 | female | 2 | 49 | 4.7 | 7 | carboplatin + paclitaxel + pembrolizumab | 7.9 | true | MSS | 2026-03-15T05:36:00.787963+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_243262 | REC_0014434 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 6.4 | 76 | female | 3 | 72 | 4.8 | 6 | carboplatin + paclitaxel + pembrolizumab | 17.7 | false | MSS | 2026-03-15T05:36:00.788528+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_395033 | REC_0014435 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 10.2 | 52 | male | 0 | 11 | 6.5 | 1 | sotorasib 960 mg daily | 20.8 | true | MSI-H | 2026-03-15T05:36:00.788947+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_196232 | REC_0014436 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 26 | 7.4 | 61 | male | 0 | 31 | 3.3 | 6 | pembrolizumab 200 mg q3w | 13.6 | false | MSS | 2026-03-15T05:36:00.789307+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_210232 | REC_0014437 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 14.6 | 73 | male | 1 | 1 | 6 | 1 | osimertinib 80 mg daily | 8.3 | true | MSS | 2026-03-15T05:36:00.789671+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_932109 | REC_0014438 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 4.2 | 64 | male | 1 | 28 | 5 | 4 | carboplatin + paclitaxel + pembrolizumab | 10.6 | false | MSS | 2026-03-15T05:36:00.790017+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_801723 | REC_0014439 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 12.5 | 79 | female | 1 | 15 | 7.8 | 0 | sotorasib 960 mg daily | 20.8 | false | MSS | 2026-03-15T05:36:00.790367+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_568470 | REC_0014440 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 13.4 | 61 | female | 1 | 6 | 5.3 | 7 | alectinib 600 mg BID | 4 | false | MSS | 2026-03-15T05:36:00.790747+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_235767 | REC_0014441 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 20 | 12.5 | 67 | male | 0 | 12 | 7.2 | 2 | osimertinib 80 mg daily | 12.7 | false | MSS | 2026-03-15T05:36:00.791050+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_562211 | REC_0014442 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 11.2 | 80 | female | 0 | 13 | 4.3 | 7 | entrectinib 600 mg daily | 13.1 | true | MSI-H | 2026-03-15T05:36:00.791357+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_998659 | REC_0014443 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 15.3 | 67 | female | 0 | 7 | 4.5 | 4 | sotorasib 960 mg daily | 16.4 | false | MSS | 2026-03-15T05:36:00.791654+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_489286 | REC_0014444 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 27 | 10.4 | 73 | female | 3 | 17 | 3.9 | 1 | entrectinib 600 mg daily | 9.6 | true | MSS | 2026-03-15T05:36:00.792212+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_926874 | REC_0014445 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 5.2 | 55 | female | 1 | 25 | 5.2 | 6 | carboplatin + paclitaxel + pembrolizumab | 9.8 | false | MSS | 2026-03-15T05:36:00.792603+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_913202 | REC_0014446 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 16 | 11.2 | 73 | female | 1 | 17 | 5.7 | 1 | entrectinib 600 mg daily | 15.8 | true | MSI-H | 2026-03-15T05:36:00.792931+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_936328 | REC_0014447 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 12.7 | 71 | female | 1 | 18 | 2.8 | 3 | osimertinib 80 mg daily | 21.7 | true | MSI-H | 2026-03-15T05:36:00.793266+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_514780 | REC_0014448 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 10 | 68 | female | 0 | 7 | 7.4 | 1 | alectinib 600 mg BID | 20.6 | false | MSI-H | 2026-03-15T05:36:00.793620+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_829455 | REC_0014449 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 16 | 14 | 78 | female | 2 | 14 | 4 | 1 | entrectinib 600 mg daily | 23.1 | true | MSI-H | 2026-03-15T05:36:00.793954+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_254572 | REC_0014450 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 31 | 16.3 | 65 | female | 0 | 8 | 5.1 | 5 | alectinib 600 mg BID | 13 | false | MSS | 2026-03-15T05:36:00.794269+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_967185 | REC_0014451 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 15.8 | 64 | male | 1 | 14 | 5.9 | 8 | entrectinib 600 mg daily | 14.8 | false | MSS | 2026-03-15T05:36:00.794599+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_428700 | REC_0014452 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 16.6 | 62 | male | 0 | 15 | 3.7 | 5 | sotorasib 960 mg daily | 9 | false | MSI-H | 2026-03-15T05:36:00.794916+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_976440 | REC_0014453 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 12.9 | 53 | male | 0 | 22 | 5.8 | 4 | sotorasib 960 mg daily | 10.3 | false | MSI-H | 2026-03-15T05:36:00.795226+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_634337 | REC_0014454 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 5.9 | 65 | female | 1 | 16 | 6.3 | 7 | alectinib 600 mg BID | 4.4 | true | MSS | 2026-03-15T05:36:00.795541+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_931626 | REC_0014455 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 8.4 | 77 | female | 0 | 12 | 5.1 | 6 | alectinib 600 mg BID | 5.7 | false | MSS | 2026-03-15T05:36:00.795854+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_108749 | REC_0014456 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 22 | 3.6 | 75 | female | 1 | 25 | 4.9 | 0 | carboplatin + paclitaxel + pembrolizumab | 50.8 | true | MSS | 2026-03-15T05:36:00.796254+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_831547 | REC_0014457 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 18.5 | 63 | male | 1 | 2 | 5.3 | 4 | entrectinib 600 mg daily | 11.3 | true | MSS | 2026-03-15T05:36:00.796933+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_297922 | REC_0014458 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 6 | 64 | male | 0 | 37 | 5.4 | 3 | carboplatin + paclitaxel + pembrolizumab | 10.6 | true | MSS | 2026-03-15T05:36:00.797365+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_159125 | REC_0014459 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 13 | 82 | male | 2 | 8 | 4.9 | 2 | sotorasib 960 mg daily | 27.1 | true | MSS | 2026-03-15T05:36:00.797761+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_596427 | REC_0014460 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 14.9 | 63 | male | 0 | 11 | 5.4 | 4 | osimertinib 80 mg daily | 5.7 | true | MSI-H | 2026-03-15T05:36:00.798356+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_573307 | REC_0014461 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 18 | 7.8 | 74 | female | 2 | 20 | 4.8 | 2 | sotorasib 960 mg daily | 21.2 | false | MSS | 2026-03-15T05:36:00.798762+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_865317 | REC_0014462 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 4.4 | 80 | female | 2 | 6 | 4.2 | 6 | entrectinib 600 mg daily | 14.7 | true | MSS | 2026-03-15T05:36:00.804481+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_553983 | REC_0014463 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 31 | 16.8 | 74 | female | 1 | 12 | 6.5 | 0 | osimertinib 80 mg daily | 19.2 | true | MSI-H | 2026-03-15T05:36:00.804985+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_161835 | REC_0014464 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 10.6 | 85 | female | 1 | 7 | 6.1 | 2 | osimertinib 80 mg daily | 33.4 | true | MSI-H | 2026-03-15T05:36:00.805382+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_278573 | REC_0014465 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 8.7 | 64 | female | 1 | 0 | 5.9 | 1 | osimertinib 80 mg daily | 8.5 | false | MSS | 2026-03-15T05:36:00.805766+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_338503 | REC_0014466 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 22 | 4.4 | 72 | female | 2 | 23 | 5.5 | 5 | pembrolizumab 200 mg q3w | 13.8 | false | MSS | 2026-03-15T05:36:00.806128+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_129153 | REC_0014467 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 29 | 16.8 | 60 | female | 1 | 16 | 7 | 2 | sotorasib 960 mg daily | 17 | true | MSS | 2026-03-15T05:36:00.806491+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_583943 | REC_0014468 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 31 | 10 | 74 | female | 2 | 11 | 6.5 | 0 | alectinib 600 mg BID | 54 | false | MSS | 2026-03-15T05:36:00.806858+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_895717 | REC_0014469 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 14.2 | 54 | female | 0 | 10 | 5.6 | 1 | sotorasib 960 mg daily | 27.1 | true | MSS | 2026-03-15T05:36:00.807273+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_695157 | REC_0014470 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 8.4 | 68 | female | 1 | 5 | 3.1 | 1 | sotorasib 960 mg daily | 17.5 | false | MSS | 2026-03-15T05:36:00.807799+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_779992 | REC_0014471 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 6.6 | 83 | female | 2 | 61 | 3.9 | 6 | carboplatin + paclitaxel + pembrolizumab | 12.2 | true | MSS | 2026-03-15T05:36:00.808938+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_637286 | REC_0014472 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 31 | 6.4 | 66 | female | 0 | 45 | 6 | 2 | carboplatin + paclitaxel + pembrolizumab | 19.8 | false | MSS | 2026-03-15T05:36:00.809441+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_454693 | REC_0014473 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 14.8 | 57 | male | 1 | 20 | 7.6 | 1 | sotorasib 960 mg daily | 19.2 | true | MSS | 2026-03-15T05:36:00.809826+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_496107 | REC_0014474 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 31 | 8.5 | 73 | male | 2 | 18 | 6.5 | 5 | osimertinib 80 mg daily | 12.7 | false | MSS | 2026-03-15T05:36:00.810198+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_785428 | REC_0014475 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 16.1 | 70 | female | 1 | 18 | 5.1 | 1 | osimertinib 80 mg daily | 10.5 | false | MSI-H | 2026-03-15T05:36:00.810555+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_201928 | REC_0014476 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 13 | 14.9 | 77 | female | 2 | 7 | 5.6 | 5 | alectinib 600 mg BID | 17 | false | MSI-H | 2026-03-15T05:36:00.810942+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_988538 | REC_0014477 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 4.3 | 62 | male | 0 | 44 | 4.2 | 4 | carboplatin + paclitaxel + pembrolizumab | 12.5 | true | MSS | 2026-03-15T05:36:00.811287+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_916005 | REC_0014478 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 27 | 18.2 | 64 | female | 1 | 25 | 4.1 | 2 | entrectinib 600 mg daily | 12 | true | MSS | 2026-03-15T05:36:00.811645+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_455504 | REC_0014479 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 11.8 | 63 | male | 1 | 17 | 5.9 | 8 | osimertinib 80 mg daily | 8 | true | MSI-H | 2026-03-15T05:36:00.812015+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_800718 | REC_0014480 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 6.6 | 69 | male | 1 | 16 | 3.4 | 8 | sotorasib 960 mg daily | 9.8 | false | MSS | 2026-03-15T05:36:00.812502+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_295400 | REC_0014481 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 11.1 | 61 | male | 1 | 26 | 5.2 | 4 | entrectinib 600 mg daily | 8.5 | true | MSS | 2026-03-15T05:36:00.812854+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_162801 | REC_0014482 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 29 | 9.9 | 69 | female | 0 | 2 | 3.9 | 1 | alectinib 600 mg BID | 13.2 | false | MSS | 2026-03-15T05:36:00.813192+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_741868 | REC_0014483 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 17 | 10.5 | 72 | male | 1 | 22 | 7.3 | 6 | alectinib 600 mg BID | 10.4 | true | MSS | 2026-03-15T05:36:00.813780+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_784471 | REC_0014484 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 10.4 | 69 | female | 1 | 12 | 6.3 | 6 | alectinib 600 mg BID | 14.4 | false | MSI-H | 2026-03-15T05:36:00.814207+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_660230 | REC_0014485 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 26 | 6.8 | 73 | female | 0 | 6 | 4.4 | 1 | pembrolizumab 200 mg q3w | 12.3 | true | MSS | 2026-03-15T05:36:00.814580+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_348043 | REC_0014486 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 13.7 | 74 | female | 2 | 18 | 4.1 | 1 | sotorasib 960 mg daily | 16.5 | false | MSS | 2026-03-15T05:36:00.814931+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_346402 | REC_0014487 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 16.2 | 53 | female | 0 | 7 | 7.3 | 4 | osimertinib 80 mg daily | 5.4 | true | MSI-H | 2026-03-15T05:36:00.815323+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_375211 | REC_0014488 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 18.4 | 65 | male | 0 | 3 | 5.4 | 4 | osimertinib 80 mg daily | 4 | false | MSI-H | 2026-03-15T05:36:00.815728+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_408074 | REC_0014489 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 13.1 | 67 | female | 1 | 17 | 5.8 | 5 | entrectinib 600 mg daily | 8.7 | false | MSI-H | 2026-03-15T05:36:00.816186+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_810025 | REC_0014490 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 18 | 13.9 | 75 | male | 2 | 14 | 3.6 | 5 | entrectinib 600 mg daily | 14.5 | true | MSI-H | 2026-03-15T05:36:00.816606+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_330053 | REC_0014491 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 23 | 6.3 | 67 | female | 0 | 39 | 6 | 0 | carboplatin + paclitaxel + pembrolizumab | 48 | true | MSS | 2026-03-15T05:36:00.817023+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_417192 | REC_0014492 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 39 | 11.3 | 60 | male | 1 | 19 | 4.2 | 6 | osimertinib 80 mg daily | 13.2 | false | MSS | 2026-03-15T05:36:00.817452+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_527150 | REC_0014493 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 29 | 11.8 | 72 | male | 1 | 19 | 4 | 1 | entrectinib 600 mg daily | 24.6 | true | MSS | 2026-03-15T05:36:00.817835+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_501107 | REC_0014494 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 7.7 | 60 | female | 0 | 9 | 4.2 | 1 | entrectinib 600 mg daily | 13.6 | false | MSS | 2026-03-15T05:36:00.818229+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_612963 | REC_0014495 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 24 | 8.4 | 66 | female | 1 | 55 | 4.4 | 4 | pembrolizumab 200 mg q3w | 14.6 | true | MSS | 2026-03-15T05:36:00.818698+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_107145 | REC_0014496 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 24 | 18.6 | 67 | female | 0 | 15 | 6 | 4 | pembrolizumab 200 mg q3w | 5 | false | MSI-H | 2026-03-15T05:36:00.819292+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_138961 | REC_0014497 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 2.1 | 61 | male | 0 | 24 | 7.5 | 5 | carboplatin + paclitaxel + pembrolizumab | 13.5 | false | MSS | 2026-03-15T05:36:00.819745+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_423350 | REC_0014498 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 7.6 | 71 | female | 2 | 7 | 4 | 2 | entrectinib 600 mg daily | 10.2 | true | MSS | 2026-03-15T05:36:00.820204+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_364596 | REC_0014499 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 29 | 3.1 | 73 | female | 2 | 13 | 6.1 | 2 | pembrolizumab 200 mg q3w | 9.2 | true | MSS | 2026-03-15T05:36:00.820603+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_233609 | REC_0014500 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 13.7 | 68 | male | 0 | 10 | 6 | 2 | alectinib 600 mg BID | 10.7 | true | MSI-H | 2026-03-15T05:36:00.821022+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.